This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Smart Insulin (LLY)

Eli Lilly & Company

Description: Smart Insulin (LLY) consists of a molecule that attaches to insulin and only releases it when blood glucose levels rise past a certain level. It is an insulin program that reportedly involves release of more insulin when blood sugar rises, but when sugar levels reduce, insulin is taken back out of circulation again.

Deal Structure: Glycostasis and Eli Lilly
In February 2016, Glycostasis, a startup company incubated at the Pacific Northwest Diabetes Research Institute (PNDRI), announced that it has been acquired by Eli Lilly and Company. Glycostasis has invented a new technology aimed at smart insulin, which could improve glucose control in people living with diabetes. Lilly is acquiring the technology for further development.

Smart Insulin (LLY) News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug